Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 15 • N.3/2024
Amgen is delighted to announce the launch of the PCSK9 Competitive Grant Program, which will provide an opportunity for investigators from around the world to compete for individual grants of up to $200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.
The program is global in reach and is open to proposals from established and junior investigators.The PCSK9 Competitive Grant Program aims to advance the science of PCSK9, especially at the junction with atherosclerosis and atherosclerosis-related mechanisms.
Specific scientific areas of research include:
- Interaction between PCSK9 and lipoprotein and remnant particle
- PCSK9 and non-low-density lipoprotein receptor effects
- PCSK9 and immune function Effects of PCSK9 on vascular wall biology through genetic, proteomic, and metabolic studies
- Lipid kinetics in patients with familial hypercholesterolemia, metabolic syndrome, or diabetes
- PCSK9 homeostasis
- PCSK9 and pancreatic β cells
- PCSK9 and neurocognition
- Other potential areas of PCSK9 research that are not out of scope
The following topics are considered out of scope and thus are not eligible for the PCSK9 Competitive Grant Program:
- All proposals not related to PCSK9
- Any research proposal involving the use of a PCSK9 inhibitor
The deadline for applications is: Friday, May 11, 2018 (11.59 pm US Pacific Time)
Bologna, 1-3 dicembre 2024
Abstract deadline
7 ottobre 2024
Perugia, 7 Dicembre 2024
[continua a leggere]Ancona, 4-5 Ottobre 2024
[continua a leggere]Modena, 4-5 Luglio 2024
[continua a leggere]Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 15 • N.3/2024
Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 5 • N.1/2023
Nuovo sito dedicato al Progetto LIPIGEN
Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina
PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina
Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)
E' necessario essere loggati come utente del Gruppo GILA per poter accedere
Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)
Pagina informativa per medici e pazienti